Journal: Journal of Bone Oncology

Article Title: Doxorubicin enhances adipogenesis in an FGF2-dependent manner and induces a tumour-promoting secretory phenotype

doi: 10.1016/j.jbo.2026.100754

Figure Lengend Snippet: Doxorubicin increases both intracellular and secreted protein levels of FGF2, and depletion of FGF2 impedes doxorubicin-enhanced adipogenesis. A) Protein expression of FGF2 at day 10 following treatment with vehicle control or 25 nM doxorubicin at day 9. Densitometry of FGF2 bands normalized to GAPDH as an endogenous loading control is shown for the high molecular weight (HMW) and low molecular weight (LMW) isoforms from 3 independent biological replicate blots. B) Secreted FGF2 (pg/mL) as detected by ELISA in conditioned supernatant at day 10 following vehicle control or 25 nM doxorubicin treatment at day 9 of adipogenic differentiation. C) Schematic for adipogenic differentiation of human MSC treated on day 9 of differentiation with vehicle control or 25 nM doxorubicin and subsequently transfected with 100 nM non-targeting siRNA or siRNA targeting FGF2 and assessed at day 12 by RT-qPCR and BODIPY staining. D) RNA isolated as per (C), was used to confirm siRNA-mediated depletion of FGF2 gene expression by RT-qPCR. E) Representative images of BODIPY stained cells treated as per (C) (left), with fold change in the percentage of BODIPY+ cells with doxorubicin treatment as compared to the vehicle control treatment for each siRNA condition enumerated and graphically represented (right). F) Gene expression of PPARG was measured using RT-qPCR at day 12 following treatment as in (C). Graphs show the mean ± SEM. Statistical tests are unpaired t -test in Fig A) and B) and one-way ANOVA in Fig D), E) and F) (*p < 0.05; **p < 0.01; ***p < 0.001), n = 3 biological replicates each with 3 technical replicates.

Article Snippet: ELISA to measure protein concentration of FGF2 in conditioned supernatants was performed using the Quantikine ELISA kit (cat #DFB50, R&D Systems, Minneapolis, MN), according to manufacturer’s instructions.

Techniques: Expressing, Control, High Molecular Weight, Molecular Weight, Enzyme-linked Immunosorbent Assay, Transfection, Quantitative RT-PCR, Staining, Isolation, Gene Expression

Journal: Frontiers in Physiology

Article Title: Uncovering the mechanism of arecoline’s effect on oral submucous fibrosis: integrating transcriptomics and in vitro and in vivo experiments

doi: 10.3389/fphys.2026.1768602

Figure Lengend Snippet: Arecoline-induced fibrosis in hOMF cells. (A) Experimental design flowchart; (B) Effects of different doses of arecoline on hOMF cell viability at 24h ( x ¯ ±s, n = 3); (C) Effects of different doses of arecoline on hOMF cell viability at 48h ( x ¯ ±s, n = 3); (D) Effects of different doses of arecoline on hOMF cell viability at 72h ( x ¯ ±s, n = 3); (E) Immunofluorescence staining of α-SMA expression in hOMF cells treated with arecoline (n = 3); (200x); (F) Immunofluorescence staining of Col1a1 expression in hOMF cells treated with arecoline (n = 3); (200x); (G) Quantitative analysis of α-SMA fluorescence intensity ( x ¯ ± s , n = 3); (H) Quantitative analysis of Col1a1 fluorescence intensity ( x ¯ ±s, n = 3). (I) Protein expression levels of bFGF ( x ¯ ±s, n = 3); (J) Protein expression levels of TGF-β1 ( x ¯ ±s, n = 3); (K) Relative mRNA expression levels of YAP ( x ¯ ±s, n = 3); (L) Relative mRNA expression levels of TAZ ( x ¯ ±s, n = 3). Compared with the Control group, * P < 0.05, ** P < 0.01.

Article Snippet: Primers were designed by Wuhan Kingwell Biotechnology Co., Ltd. TGF-β (E-EL-0162) and bFGF (E-EL-H6042) ELISA kits, as well as the Enhanced Cell Counting Kit 8 (WST-8/CCK8) (E-CK-A362), were purchased from Elabscience Biotechnology (Wuhan, China).

Techniques: Immunofluorescence, Staining, Expressing, Fluorescence, Control